ALLO Share Price Performance
US$2.53
0.60 (31.09%)
58.1% overvalued intrinsic discount
US$1.60
Fair Value
Price US$2.53
AnalystLowTarget US$1.60
Fair ValueUS$1.60
Share Pricen/a
Allogene Therapeutics, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 28 Fair Values set on narratives written by author
ALLO Community Narratives
AN
Fair Value US$1.6 58.1% overvalued intrinsic discount
Allogeneic CAR T Expectations Will Likely Disappoint As Trial And Cash Runway Risks Mount
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Allogeneic CAR T Expectations Will Likely Disappoint As Trial And Cash Runway Risks Mount
Catalysts About Allogene Therapeutics Allogene Therapeutics is a biotechnology company focused on developing off the shelf allogeneic CAR T cell therapies for cancer and autoimmune diseases. What are the underlying business or industry changes driving this perspective?Read more
0
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$1.6
58.1% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Profit Margin
10.89%
Future PE
51.85kx
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Allogeneic CAR T Expectations Will Likely Disappoint As Trial And Cash Runway Risks Mount
Fair Value: US$1.6 58.1% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Allogene Therapeutics, Inc. Key Details
About ALLO
- Founded
- 2017
- Employees
- 228
- CEO
- WebsiteView website
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
